HOME >> MEDICINE >> NEWS
UCSF begins study testing antiviral drug tenofovir to prevent HIV infection

UCSF researchers have been funded by the National Institutes of Health to study the antiretroviral drug tenofovir as a potential pre-exposure prophylaxis in Cambodia among high-risk, HIV-uninfected women. The research will look at safety and effectiveness of the drug in preventing the acquisition of HIV.

"With both a vaccine and a microbicide many years down the road, we are hoping that this once-a-day pill--a potent, low toxicity medication used in anti-HIV combination therapy--can be taken by uninfected people at high risk for HIV infection and will keep them from becoming infected," said study principal investigator, Kimberly Page Shafer, PhD, MPH, assistant professor of medicine at the UCSF Center for AIDS Prevention Studies (CAPS).

Although studies of tenofovir to prevent HIV transmission in animals have been promising, the effectiveness of this drug for preventing HIV-1 transmission in people is not known and will be evaluated in the planned research. The study will recruit 800 adult HIV-uninfected women who are at high risk for HIV infection. The study will be a randomized, double blind clinical trial with participants chosen at random to receive either tenofovir or a placebo.

Participants will take one pill a day for 12 months. At the beginning and once a month during the trial, study subjects will receive counseling to reduce risky behavior, free condoms, and free screening and treatment of sexually transmitted infections.

Participants will be tested monthly for HIV and those who become infected during the study will be referred to an HIV treatment clinic for comprehensive care, including anti-HIV therapy if medically indicated. Effectiveness will be determined by comparing HIV infection rates between the group taking tenofovir and the one taking the placebo.

Study participants will be monitored for drug safety and adverse effects. Drug safety will be examined by comparing the occurrence of side effects in th
'"/>

Contact: Jeff Sheehy
jsheehy@psg.ucsf.edu
415-597-8165
University of California - San Francisco
17-Sep-2003


Page: 1 2

Related medicine news :

1. Hopkins begins human trials with donor adult stem cells to repair muscle damaged from heart attack
2. EuroVacc 02 HIV vaccine trial begins in February 2005
3. PENN begins clinical trial of newest technology to treat thoracic aortic aneurysms
4. International trial of two microbicides begins
5. NIAID begins enrolling volunteers for novel HIV vaccine study
6. National Center for Children Exposed to Violence begins annual conference today
7. Enrollment begins for osteoarthritis initiative
8. Patients should be consulted before dialysis treatment begins
9. Clinical trial of new TB vaccine begins
10. First US tuberculosis vaccine trial in 60 years begins
11. UB begins groundbreaking study on net effect on patients of HIV treatments, other drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/11/2019)... ... , ... Autopsies don’t lie. They report the causes of death as ... harms the heart. It increases risks of heart attack and death. Autopsies ... damage occurs. , An August 1, 2019 article in U.S. News ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... the team. Dr. Hesano is an understanding, caring and highly skilled Obstetrician/Gynecologist. ... obstetrical medicine. Dr. Hesano strives to ensure that each visit is comfortable, patient-focused, ...
(Date:9/9/2019)... ... September 09, 2019 , ... ST Engineering ... International will integrate the iDirect iQ 200 Board and the latest Evolution® software ... for first responders. The iQ 200 Board will enable the HARRIER solution to ...
(Date:9/9/2019)... ... September 09, 2019 , ... On ... organization-wide policy focusing on a diabetes-language movement (#LanguageMatters) to include oral and written ... non-judgmental, free from stigma, respectful and inclusive, empowering, and person-centered (to include care ...
(Date:9/8/2019)... ... 2019 , ... The reviews from patients of ABM Medical Clinic who have ... and pain free fat loss system, has patients booking their sessions and recommending this ... uses state of the art technology incorporating radio frequency and heat to rid the ...
Breaking Medicine News(10 mins):
(Date:9/11/2019)... ... September 11, 2019 , ... HOLLOWAY AMERICA, a leading manufacturer ... beverage to pharma and chemical, recently announced it will showcase its problem-solving vessels and ... , HOLLOWAY AMERICA’s first stop will be at ISPE San Diego’s 27th Life ...
(Date:9/11/2019)... ... 2019 , ... Pivot Point Consulting is excited to announce ... Partnerships team. Maris brings two decades of experience with Cerner—leading both sales ... as a Technical Implementation Leader representing the Technical Engagement Leader community. , Pivot ...
(Date:9/9/2019)... , ... September 09, 2019 , ... ... Shoreline Periodontics & Dental Implants host the latest course in their Synergy Study ... Mystic, CT and features guest speaker Dr. Peter Barndt. Synergy Study Club brings ...
Breaking Medicine Technology:
Cached News: